| 李东玲,周京旭,朱茗祺,陈泽仁,韩甜甜.西妥昔单抗和贝伐珠单抗治疗晚期结直肠癌的有效性和安全性比较[J].,2019,19(8):1482-1485 |
| 西妥昔单抗和贝伐珠单抗治疗晚期结直肠癌的有效性和安全性比较 |
| Comparison of the Efficacy and Safety of Cetuximab and Bevacizumab in the Treatment of Advanced Colorectal Cancer |
| 投稿时间：2018-11-08 修订日期：2018-11-30 |
| DOI：10.13241/j.cnki.pmb.2019.08.018 |
| 中文关键词: 西妥昔单抗 贝伐珠单抗 晚期结直肠癌 有效性 安全性 |
| 英文关键词: Cetuximab Bevacizumab Advanced colorectal cancer Efficacy Adverse reactions |
| 基金项目:广东省科技计划项目（2012B031800207） |
|
| 摘要点击次数: 824 |
| 全文下载次数: 727 |
| 中文摘要: |
| 摘要 目的：比较西妥昔单抗和贝伐珠单抗治疗晚期结直肠癌的有效性和安全性。方法：选取2014年1月~2017年8月我院收治的晚期结直肠癌患者100例，根据患者入院先后顺序随机分为两组，所有患者均给予FOLFIRI方案进行化疗，A组在化疗的基础上给予贝伐珠单抗进行治疗，B组在化疗的基础上给予西妥昔单抗进行治疗。比较两组患者临床治疗的缓解率、控制率及不良反应的发生情况，对所有患者随访1年，记录并比较两组患者的无进展生存期。结果：两组患者的缓解率、控制率、恶心呕吐、头晕、延迟性腹泻、肝肾损伤、白细胞减少、血小板减少和尿蛋白的发生率相比均无统计学差异(P＞0.05)，但B组患者骨髓抑制和皮疹的发生率显著高于A组(P＜0.05)；两组患者的无进展生存期相比无统计学差异(P＞0.05)。结论：西妥昔单抗和贝伐珠单抗治疗晚期结直肠癌的临床效果相当，且不良反应较轻，以Ⅰ~Ⅱ度为主，患者均可耐受，对症治疗后均有所缓解。西妥昔单抗易引发骨髓抑制和皮疹，在临床应用过程中需注意并进行有效预防和积极处理。 |
| 英文摘要: |
| ABSTRACT Objective: To compare the efficacy and safety of cetuximab and bevacizumab in the treatment of advanced colorectal cancer. Methods: 100 patients with advanced colorectal cancer admitted to our hospital from January 2014 to August 2017 were selected and divided into two groups according to the sequence of admission. All the patients were treated with FOLFIRI for chemotherapy, group A was treated with bevacizumab on the basis of chemotherapy, and group B was treated with cetuximab on the basis of chemotherapy. The remission rate, control rate and incidence of adverse reactions were compared between the two groups. All patients were followed up for 1 year, and no progression-free survival was recorded and compared between the two groups. Results: There was no statistical difference in the remission rate and control rate between the two groups (P>0.05). In terms of adverse reactions, there were no statistically significant difference between the two groups in the incidence of nausea and vomiting, dizziness, delayed diarrhea, liver and kidney injury, leukopenia, thrombocytopenia and urinary protein (P>0.05), but the incidence of bone marrow suppression and rash in group B was significantly higher than that in group A (P<0.05). There was no statistically significant difference in the progression-free survival between the two groups (P>0.05). Conclusion: Cetuximab and bevacizumab had equal clinical effects in the treatment of advanced colorectal cancer. But cetuximab could easy cause bone marrow suppression and rash, which should be paid attention to in the process of clinical application and effective prevention and active treatment. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
